Substandard application of preimplantation genetic screening may interfere with its clinical success
Received 29 July 2007; received in revised form 3 August 2007; accepted 3 August 2007.
The intent of this study was to evaluate a recent randomized clinical trial evaluating the effect of preimplantation genetic screening (PGS) that reports a negative effect on pregnancy outcome. This article reviews appropriate PGS techniques and how they differ from the trial in question. A closer look at the clinical trial in question reveals significant lack of expertise in biopsy, cell fixation, genetic analysis, and patient selection. At most, this trial demonstrates that in inexperienced hands, PGS can be detrimental. No other conclusions concerning the effect of PGS on pregnancy results can be drawn from the trial.
hFlorida International University College of Medicine, Miami, Florida
Reprint requests: Santiago Munné, Ph.D., Reprogenetics, 3 Regent Street, Suite 301, Livingston, New Jersey 07039 (FAX: 973-992-1423).
S.M. is Director of Reprogenetics, a laboratory specializing in preimplantation genetic diagnosis. I.T.-K. has received research funding from Serono and is on the speaker's bureau for Organon. M.S. has a financial interest in Reprogenetics. Y.V. is owner and chief executive officer of Reproductive Genetics Institute, which operates clinics that provide preimplantation genetic diagnosis. J.L.S. is a member of the medical advisory board for Biocept and is a member of the scientific advisory board for IMETRIKUS.
ABSTRACT